
NASA's SpaceX Crew-11 successfully launches to ISS to replace Spokane astronaut Anne McClain and company
NASA's SpaceX Crew-11 is on its way to relieve U.S. Army Colonel Anne McClain and company aboard the International Space Station after successfully launching from Cape Canaveral Friday at 8:43 a.m. Pacific Time.
The arrival of the SpaceX Dragon capsule carrying Crew-11, which is composed of NASA astronauts Zena Cardman and Mike Fincke, Japanese Aerospace Exploration Agency (JAXA) astronaut Kimiya Yui and Roscosmos cosmonaut Olege Platonov, is expected to occur around midnight Saturday morning. It will be mission commander Cardman and mission specialist Platonov's first spaceflights, while pilot Fincke and specialist Yui are beginning their fourth and second stint aboard the station.
"I have no emotions but joy right now," Cardman said shortly after the Dragon capsule achieved orbit. "That was absolutely transcendent, the ride of a lifetime."
McClain and her fellow members of Crew-10 will return after a brief handover period with their staffing replacements aboard the orbiting laboratory.
"They'll join the crew that's in orbit, they'll hand over there, they'll learn as much as they can about the station from that crew and then we'll switch our emphasis to bringing home Crew-10 sometime, we hope, next week," said Ken Bowersox, associate administrator of NASA's Space Operations Mission Directorate. "If weather and hardware cooperate."
McClain shared via social media Wednesday that she and fellow NASA astronaut Nichole Ayers, JAXA astronaut Takuya Onishi and Roscosmos cosmonaut Kirill Peskov are hard at work preparing for their successors' arrival. They are currently expected to undock from the space station no sooner than 11 a.m. Wednesday, splashing down off the coast of California just over six hours later, McClain said.
On Thursday, McClain took to social media again to share one of the last photos she'll snap aboard the space station: an image of the Northern Lights dancing just above the curve of the Earth as seen from the station's cupola.
"As we get close to leaving the International Space Station, I find myself wanting to savor every moment and every view," McClain wrote. "None of us are guaranteed to get to do this again, and every minute spent in space is a special one."
Steve Stich, manager of NASA's Commercial Crew Program, said in a Friday news conference that the Crew-11 launch was initially delayed from Thursday due to inopportune weather but went off without issue, shortly before the Florida weather almost necessitated another delay. The flight is the 12th human space flight and 11th space station crew change to come out of NASA's commercial crew program, in which the space agency partners with corporations in order to make the staffing of the space lab safer and more reliable and cost efficient.
"We really got very lucky today, I would say," Stich said. "I was just looking at a shot on my phone, a view from Falcon 9 looking down, and you can see the launch pad was kind of in a little, it was almost like a horseshoe of clouds. The launch pad was in the center of that horseshoe."
Sarah Walker, director of Dragon Mission Management for SpaceX, added that while it was disappointing to scrub Thursday's launch with less than a minute to take off, safety is always the number one priority.
"Today was a better day to fly, although, just barely," Walker said. "I want to say that that horseshoe of clouds closed within a couple of minutes of T-Zero."
Once aboard, Crew-11 will continue the research conducted aboard the station for decades. The International Space Station has been staffed by astronauts and cosmonauts since 2000, with visits from more than 280 people hailing from 26 countries. Breakthroughs and findings aboard the laboratory have helped make major advancements in space travel, medicine and natural disaster preparedness, just to name a few.
Dana Weigel, manager of NASA's ISS program, said Crew-11 will have the opportunity to partake in some particularly "key" research as the agency prepares for the Artemis program, and possible Mars missions. Those include studies on the astronauts themselves that seek to protect human health during longer missions and simulated lunar lands in a region that mimic the Moon's South Pole.
"The goal of this study is to really understand how the disorienting effects of microgravity impact piloting and landing, and then we'll take that feedback and we'll put that into our planning for tools and aids for the crew," Weigel said.
The Artemis program seeks to return American astronauts to the moon for the first time since the Apollo missions of the 1960s and early '70s, and McClain was among those in the running for one of the program's missions prior to her naming to Crew-10. The 46-year-old now has two spaceflights under her belt totaling more than 340 days and counting, making her an attractive option for future Artemis missions.
Cardman and the rest of Crew-11's mission is months longer than Crew-10's stay, and they will be among a handful of people to be aboard the station in November as NASA and its commercial and international partners celebrate 25 years of continual human occupancy. Weigel thanked all of those who have made reaching the notable milestone possible, and shared that the agency is working through a variety of ideas to commemorate the "amazing accomplishment" in the months to come.
"We have no shortage of ideas for what everyone would like to do to celebrate," Weigel said with a smile.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
BMI OrganBank is developing novel medical devices with potential to significantly reduce the waitlist for lifesaving organ transplants, beginning with kidneys FDA Breakthrough Device Designation secures expedited FDA engagement in advance of clinical studies planned for early next year WINSTON-SALEM, N.C., Aug. 4, 2025 /PRNewswire/ -- BMI OrganBank, a pioneering leader in organ assessment and preservation, proudly announces that its revolutionary organ preservation device has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation, granted for their kidney preservation device, underscores BMI OrganBank's commitment to advancing transformative technologies that will significantly improve outcomes for transplant patients. With current kidney perfusion technologies, which use cold storage temperatures, it is difficult to evaluate the function of kidneys before transplant. Furthermore, they are vulnerable to significant injury during the storage period before transplantation. As such, a large proportion of donated kidneys remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends to increase the number of kidneys available for transplant and address stubbornly long kidney transplant waitlist times. A clinical study is planned for early next year. "We are incredibly honored to receive this significant designation from the FDA and look forward to working with them as we prepare for clinical studies" stated Carrie DiMarzio, Chief Executive Officer and Co-Founder. David A. Gerber, MD, abdominal transplant surgeon and Chief Medical Officer stated "We are energized by our promising preclinical data. The timing of this news is outstanding as my colleagues and I participate in the World Transplant Congress this week." About BMI OrganBank® BMI OrganBank specializes in developing transformative perfusion systems for organ and tissue evaluation and preservation. With facilities at the Innovation Quarter in Winston-Salem, NC, and Research Triangle Park, NC, the company is advancing multiple medical devices that use its patented and proprietary technologies. Its flagship product, the portable OrganBank kidney device, was co-developed with leading transplant surgeons and is set to begin clinical studies soon. Learn more at View original content to download multimedia: SOURCE BMI OrganBank Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press
an hour ago
- Associated Press
BMI OrganBank Secures FDA Breakthrough Device Designation for Innovative Kidney Transplant Technology
WINSTON-SALEM, N.C., Aug. 4, 2025 /PRNewswire/ -- BMI OrganBank, a pioneering leader in organ assessment and preservation, proudly announces that its revolutionary organ preservation device has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation, granted for their kidney preservation device, underscores BMI OrganBank's commitment to advancing transformative technologies that will significantly improve outcomes for transplant patients. With current kidney perfusion technologies, which use cold storage temperatures, it is difficult to evaluate the function of kidneys before transplant. Furthermore, they are vulnerable to significant injury during the storage period before transplantation. As such, a large proportion of donated kidneys remain unused. BMI OrganBank's groundbreaking room temperature machine perfusion (RTMP) platform, developed in collaboration with leading transplant surgeons and academic medical centers, shows great promise to facilitate kidney quality assessment and extend preservation times. BMI OrganBank intends to increase the number of kidneys available for transplant and address stubbornly long kidney transplant waitlist times. A clinical study is planned for early next year. 'We are incredibly honored to receive this significant designation from the FDA and look forward to working with them as we prepare for clinical studies' stated Carrie DiMarzio, Chief Executive Officer and Co-Founder. David A. Gerber, MD, abdominal transplant surgeon and Chief Medical Officer stated 'We are energized by our promising preclinical data. The timing of this news is outstanding as my colleagues and I participate in the World Transplant Congress this week.' About BMI OrganBank® BMI OrganBank specializes in developing transformative perfusion systems for organ and tissue evaluation and preservation. With facilities at the Innovation Quarter in Winston-Salem, NC, and Research Triangle Park, NC, the company is advancing multiple medical devices that use its patented and proprietary technologies. Its flagship product, the portable OrganBank kidney device, was co-developed with leading transplant surgeons and is set to begin clinical studies soon. Learn more at View original content to download multimedia: SOURCE BMI OrganBank
Yahoo
an hour ago
- Yahoo
Box Office: ‘Fantastic Four' Craters by 66% in Second Weekend, ‘Naked Gun' Debuts to $17 Million
Marvel's First Family might not save the day after all. 'The Fantastic Four: First Steps' is quickly losing steam in its second weekend, signaling the comic book adventure isn't connecting at the box office beyond the film's core demographic of superhero fans. After a healthy $117.6 million debut, 'The Fantastic Four' suffered a hefty 66% drop in its sophomore outing with $40 million from 4,125 theaters. Heading into the weekend, box office analysts anticipated a decline of 55% to 60% from its opening. (By comparison, 'Superman' dropped by 53% in its second weekend after launching to $125 million earlier in July.) This painful fall is surprising because the Marvel tentpole has the benefit of positive reviews and word-of-mouth, as well as a clear runway in terms of competition. More from Variety 'Together' Stars Dave Franco and Alison Brie Relive Their Off-Screen Wedding: Weed Pens, Pizzeria Mozza and a Party Crasher Liam Neeson Jokes His Death as Qui-Gon Jinn in 'The Phantom Menace' Was 'A Bit Namby-Pamby': 'Please, Hardly a Master Jedi' 'Bad Guys 2' Director on Spoofing Elon Musk's SpaceX and How the Cold Open Was Influenced by 'Skyfall' and 'Mission: Impossible' Although those ticket sales were enough to rank as No. 1 on North American charts, 'The First Steps' endured one of the steeper second-weekend drops for Disney's Marvel Cinematic Universe, better than 'The Marvels' (down 78%) but in the company of February's 'Captain America: Brave New World' (down 68%), 2023's 'Ant Man and the Wasp: Quantumania' (down 70%) and 2022's 'Thor: Love and Thunder' (down 67%). So far, 'Fantastic Four' has generated $198 million domestically and $368 million globally. Luckily for Marvel, whose output has been wildly inconsistent in post-pandemic times, 'The First Steps' is pacing to outgross this year's prior theatrical disappointments of 'Captain America: Brave New World' ($415 million globally) and 'Thunderbolts' ($382 million globally). The final tally for 'Fantastic Four' won't be disastrous, à la 'The Marvels' ($206 million) or 'Thunderbolts,' but it's not yet a return to box office glory for Marvel. However, the MCU should officially regain its box office stride with its next three films — 2026's 'Spider-Man: Brand New Day' and 'Avengers: Doomsday' and 2027's 'Avengers: Secret Wars.' ''Fantastic Four' is not a top-tier Marvel franchise. Never has been,' says analyst Jeff Bock of Exhibitor Relations. 'Remember, this ramps up into 'Avengers.' That's the real payoff.' Three new movies opened nationwide, but none were competing for the same audience as 'Fantastic Four.' Among new releases, Universal and DreamWorks Animation's heist comedy 'The Bad Guys 2' enjoyed the strongest start with $22.8 million from 3,852 venues. That's directly even with the first film, which opened to $23 million in 2022 at a time when cinemas were majorly struggling to recover from COVID and studios were barely releasing any movies. The original film eventually powered to $250 million worldwide. 'The Bad Guys 2,' which cost $80 million and follows a group of reformed criminals who relapse for one final con job, was embraced by audiences with an 'A' grade on CinemaScore exit polls. Overseas, 'The Bad Guys 2' landed with $16.3 million for a global total of $44.5 million. 'This is a good opening for an animation sequel,' says analyst David A. Gross of Franchise Entertainment Research. 'With this kind of business, the movie is doing what it's supposed to do.' At No. 3, Paramount's slapstick comedy 'The Naked Gun' debuted to $17 million from 3,344 theaters, right in line with projections. The film earned another $11.5 million at the international box office, bringing its global tally to $28.5 million. It's a promising start given the dearth of theatrical comedies. Akiva Schaffer of the Lonely Island fame directed the film, which carries a $42 million price tag. Critics and moviegoers dug 'The Naked Gun,' in which Liam Neeson stars as bumbling L.A. detective Frank Drebin Jr. (son of the late Leslie Nielsen's Frank Drebin, his predecessor in the 'Naked Gun' trilogy) alongside Pamela Anderson and Paul Walter Hauser. The movie scored an 'A-' grade on CinemaScore and boasts a 90% average on Rotten Tomatoes, both of which should bode well for the remainder of its theatrical run. 'The Naked Gun' appealed almost squarely to older white men; 62% of initial crowds were male, 50% were above 35 years old and 70% were Caucasian. This weekend's final newcomer, Neon's body-horror nightmare 'Together' landed in sixth place with $6.8 million over the traditional weekend and an encouraging $10.8 million during its first five days of release. Real-life husband and wife Dave Franco and Alison Brie star in 'Together' as a co-dependent couple who become frighteningly close after a mysterious force causes horrific body changes. Audiences gave the film a 'C+' on CinemaScore, though that harsh a grade isn't surprising since they likely left the theater feeling very disturbed. In fact, Neon has been leaning into the on-screen trauma to promote the movie, offering free couples therapy for partners who see 'Together' during opening weekend. Neon shelled out $17 million to buy the movie at Sundance, marking one of the richest deals in the festival's history. 'A lukewarm audience score is typical of these films and generally has little effect on how they play out,' Gross says. 'It's [a] smart horror production that's going to be profitable when it's finished.' Elsewhere at the box office, 'Superman' descended to fourth place with $13.9 million in its fourth weekend of release. The Warner Bros. and DC Studios adaptation has generated $316.2 million domestically and $551.2 million globally to date. Universal's 'Jurassic World Rebirth' rounded out the top five with $8.4 million in its fifth weekend of release. The dinosaur epic, which rebooted the long-running property with Scarlett Johansson, Jonathan Bailey and Mahershala Ali, has grossed $317 million in North America and $766 million globally. Overall, the box office is 9.5% ahead of last year but 23% behind 2019, the last pre-pandemic year, according to Comscore. Summer revenues just hit $3 billion from May through early August, so it's a question of whether this could be the second summer in post-COVID times — the year of 'Barbenheimer' was the first — to cross the $4 billion milestone. 'A solid home stretch of the summer is in the cards,' predicts senior Comscore analyst Paul Dergarabedian. 'The $4 billion benchmark is still about a $1 billion away, which is no cake walk but potentially in play.' Solve the daily Crossword